scispace - formally typeset
S

Sally E. Self

Researcher at Medical University of South Carolina

Publications -  54
Citations -  1382

Sally E. Self is an academic researcher from Medical University of South Carolina. The author has contributed to research in topics: Kidney disease & Kidney. The author has an hindex of 20, co-authored 54 publications receiving 1188 citations.

Papers
More filters
Journal ArticleDOI

Antibody-mediated rejection in cardiac transplantation: emerging knowledge in diagnosis and management: a scientific statement from the American Heart Association.

TL;DR: The most recent International Society for Heart and Lung Transplantation (ISHLT) Consensus Conference on Antibody-Mediated Rejection (AMR) as discussed by the authors defined four diagnostic criteria: clinical, histopathologic, immunopathologic and serological assessment.
Journal Article

Characterization of a human myeloid leukemia cell line highly resistant to taxol

TL;DR: These taxol-resistant sublines of HL-60 myeloid leukemia cells may serve as in vitro experimental models for examinating strategies which may have potential applicability for overcoming taxol resistance.
Journal ArticleDOI

Prospective measure of serum 3-nitrotyrosine levels in systemic lupus erythematosus: correlation with disease activity.

TL;DR: The results of this study suggest that overproduction of NO may play a pathogenic role in SLE and lupus nephritis and Serum 3NT may be a useful, new tool for studying the contributions of NO to the pathogenesis of SLE.
Journal ArticleDOI

Prediction of urinary protein markers in lupus nephritis.

TL;DR: A list of protein spots that can be used to develop a clinical assay to predict ISN/RPS class and chronicity for patients with lupus nephritis are identified and an assay based on antibodies against these spots could eliminate the need for renal biopsy.
Journal ArticleDOI

CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease

Laura H. Mariani, +239 more
TL;DR: Study infrastructure will support a broad range of scientific approaches to identify mechanistically distinct subgroups, identify accurate biomarkers of disease activity and progression, delineate disease-specific treatment targets, and inform future therapeutic trials.